1 / 4

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., rk21n@nih , 301-648-7375

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., rk21n@nih.gov , 301-648-7375 Elizabeth Maestri, RN, maestrie@mail.nih.gov , 301-402-5633 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (multicenter)

lelia
Download Presentation

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., rk21n@nih , 301-648-7375

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., rk21n@nih.gov, 301-648-7375 • Elizabeth Maestri, RN, maestrie@mail.nih.gov, 301-402-5633 • Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (multicenter) • Multiply relapsed (prior purine analogs or purine analog + rituximab) • Recombinant immunotoxin, non-chemotherapy • No prior recombinant immunotoxin allowed • BRAF & MEK Inhibitors Dabrafenib & Trametinib for Hairy Cell Leukemia (multicenter) • Multiply relapsed (prior purine analogs or purine analog + rituximab) • Oral agents, taken daily • Must have BRAF V600E+ HCL • Randomized Phase II Trial of Rituximab With Pentostatin or Bendamustine for Multiply Relapsed HCL • Multiply relapsed • Pentostatin or bendamustine chemotherapy and rituximab monoclonal antibody • HCL or HCLv, prior recombinant immunotoxin or splenectomy allowed. • LMB-2 to Treat Hairy Cell Leukemia (NIH) • Multiply relapsed • Prior recombinant immunotoxin allowed • Recombinant immunotoxin, non-chemotherapy • Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia (NIH) • Early HCL: Newly diagnosed or once relapsed • Cladribine chemotherapy and rituximab monoclonal antibody • Multicenter study of BTK inhibitor Ibrutinib for relapsed HCL • Relapsed HCL or HCLv • Oral agent, taken daily

More Related